EUCTR2010-020912-12-FR进行中（未招募）不适用
Open-label safety study of a 1-year 20 mg dose regimen of tasimelteon for the treatment of Non-24-Hour Sleep-Wake Disorder (N24HSWD) in blind individuals with no light perception.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Ability and acceptance to provide informed consent;
- •2.Men or women between 18 – 75 years, inclusive;
- •3.Body Mass Index (BMI) of = 18 and = 33 kg/m2 (BMI = weight (kg)/ [height (m)]2);
- •4.Males, non-fecund females, or females of child-bearing potential ( defined as less than 1 year post-menopausal or not surgically sterile ) must be using an acceptable method of birth control (e.g., oral contraceptives, patch, intrauterine device [IUD], diaphragm or condom with spermicidal jelly or foam or abstinence, or cervical cap) for a period of 35 days before the first dosing and must have a negative pregnancy test at the screening and baseline visits;
- •5.Note: Women using hormonal methods of birth control (e.g. oral contraceptives, patch, and steroids) must use an additional method of birth control during the study and for one month after the last dose.
- •6.Willing and able to comply with study requirements and restrictions;
- •7.No perception of light by the patient’s own report;
- •8.Diagnosis of N24HSWD
- •a.History (within the last 3 months) of trouble sleeping at night (difficulty initiating sleep or staying asleep), difficulty awakening in the morning, or daytime sleepiness as determined by answering yes to at least one question in the Sleep Complaint Questionnaire;
- •b.An abnormal phase relationship between the circadian melatonin rhythm and their target sleep-wake cycle is established per urinary aMT6s assessment.
- •9. Affiliated with or beneficiary of a social security system
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Have a probable diagnosis of a current sleep disorder other than N24HSWD that is the primary cause of the sleep disturbance based on clinical investigator medical judgment;
- •2. History (within the 12 months prior to screening) of psychiatric disorders including Major Depressive Disorder, Generalized Anxiety Disorder, Axis II Disorders, delirium or any other psychiatric disorder that in the opinion of the clinical investigator would affect participation in the study or full compliance with study procedures;
- •3. History of intolerance and/or hypersensitivity to melatonin or melatonin agonists;
- •4. History of drug or alcohol abuse as defined in DSM-IV, Diagnostic Criteria for Drug and Alcohol Abuse, within the 12 months prior to screening and/or regular consumption of alcoholic drinks (> 40g/day);
- •5. Patients having any current suicidal ideation of type 4 or 5 on the C-SSRS at Screening or Baseline;
- •6. Patient is at risk of suicide, in the opinion of the Investigator. Evidence of suicide risk could include any suicide attempt within the past year or any other suicidal behavior within the past year;
- •7. Current clinically significant cardiovascular, respiratory, neurologic, hepatic, hematopoietic, renal, gastrointestinal or metabolic dysfunction unless currently controlled and stable;
- •8. Patients who have estimated creatinine clearance (CLcr; based on the Cockcroft-Gault equation) = to 55 mL/min;
- •9. Clinically significant deviation from normal in clinical laboratory results, vital signs measurements, or physical examination findings at screening or baseline as determined by the clinical investigator;
- •10. Indication of impaired liver function (values for AST, ALT or bilirubin > 2 times Upper Limit of Normal);
- •11. Pregnant or lactating females;
- •12. A positive test for drugs of abuse at the screening visit;
- •13. Smoke more than 10 cigarettes/day;
- •14. Participation in a previous tasimelteon (aka VEC-162 or BMS-214778) trial;
- •15. Exposure to any investigational drug, including placebo, within 30 days, 5 half-lives, or the exclusion period given by a previous study in which the patient has participated in, whichever of the three scenarios is longer.
- •16.Use of central nervous system prescription or OTC medications, other than melatonin, that affects the sleep-wake cycle within 3 weeks or 5 half-lives (whichever was longer) of Baseline;
- •17. Use of melatonin or melatonin agonist within 1 week of the urine collection for the aMT6s assessment;
- •18. Any other sound medical reason as determined by the clinical investigator.
研究者
相似试验
进行中（未招募）
1 期
Study to evaluate the safety and efficacy of Cipaglucosidase Alfa and Miglustat in pediatric subjects with late-onset Pompe diseaseate-onset Pompe diseaseMedDRA version: 20.0Level: SOCClassification code: 10010331Term: Congenital familial and genetic disorders Class: 21CTIS2022-502547-36-00Amicus Therapeutics Inc.25
招募中
3 期
ATB200/AT2221 Phase 3 Open-label Study in Pediatric SubjectPompe diseaseJPRN-jRCT2031210014Wright Jacquelyn22
招募中
不适用
A phase 1b, dose finding, open label study of the safety and tolerability of carboplatin-cyclophosphamide combined with atezolizumab, an antibody that targets programmed death ligand 1 (PD-L1), in patients with advanced breast cancer, ovarian, cervical and endometrial cancer.breast cancerNL-OMON45572ederlands Kanker Instituut12
已完成
不适用
A study of gevokizumab in subjects with Behçet?s disease uveitisBehçet?s disease uveitisSkin and Connective Tissue DiseasesBehçet's diseaseISRCTN15180871Institut de Recherches Internationales Servier (France)21
进行中（未招募）
1 期
Phase 1/2 study of IMC-M113V in virologically suppressed chronic HIV infectioCTIS2024-513938-38-00Immunocore Limited30